In search of new strategies against life-threatening tuberculosis infections, a team from the Technical University of Munich (TUM), as well as Harvard University and Texas A&M University in the USA have found a new ally. They discovered a substance that interferes with the mycomembrane formation of the bacterium. It is effective even in low concentrations and when combined with known antibiotics their effectiveness is improved by up to 100-fold.
Among the greatest challenges when treating life-threatening tuberculosis infections is the increasing resistance to antibiotics. But the pathogen itself also makes the life of doctors difficult: its dense mycomembrane hampers the effect of many medications. A team of scientists headed by Stephan A. Sieber, Professor of Organic Chemistry at TU Munich, has discovered a substance that perturbs the formation of this membrane significantly.
The mycomembrane of the tuberculosis pathogen Mycobacterium tuberculosis consists of a lipid double layer that encapsulates the cell wall, forming an exterior barrier. Structural hallmarks are mycolic acids, branched beta-hydroxy fatty acids with two long hydrocarbon chains. The team hypothesizes that similarly structured beta lactones could “mask” themselves as mycolic acid to enter the mycolic acid metabolic pathways and then block the decisive enzymes.
In the context of an extensive search, the interdisciplinary team of scientists hit the bullseye with the beta lactone EZ120. It does indeed inhibit the biosynthesis of the mycomembrane and kills mycobacteria effectively. Using enzyme assays and mass spectroscopy investigations, Dr. Johannes Lehmann, a researcher at the Chair of Organic Chemistry II at TU Munich, demonstrated during his doctoral work that the new inhibitor blocks especially the enzymes Pks13 and Ag85, which play a key role in the development of mycomembranes.
EZ120 is effective even in low doses, easily passes the mycomembrane and exhibits only low toxicity to human cells. The combined application of this substance with known antibiotics showed a synergistic effect leading to significantly increased effectiveness.”Vancomycin, a common antibiotic, and EZ120 work together very well,” says Prof. Sieber, who heads the Chair of Organic Chemistry II. “When used together, the dose can be reduced over 100-fold.
“The scientists suspect that disrupting the mycomembrane enables antibiotics to enter the bacteria more easily. This is a new mode of action and might be a starting point for novel tuberculosis therapies.
Learn more: Double strike against tuberculosis
The Latest on: Tuberculosis
- Tuberculosis vaccine may help protect against COVID-19on November 28, 2020 at 6:03 am
New research adds to the evidence suggesting that the BCG vaccine — which prevents tuberculosis — may also help protect against COVID-19.
- Scientists discover potential method to starve the bacteria that cause tuberculosison November 25, 2020 at 1:24 pm
The infectious disease Tuberculosis (TB) is one of the leading causes of death worldwide. While rates of TB in Canada have remained relatively static since the 1980s, the disease disproportionately ...
- Lung-on-chip provides new insight on body's response to early tuberculosis infectionon November 24, 2020 at 9:58 am
Scientists have developed a lung-on-chip model to study how the body responds to early tuberculosis (TB) infection, according to findings published today in eLife.
- Tuberculosis diagnosis in Rockhampton aged care worker sparks widespread screening of residents, staffon November 23, 2020 at 9:44 pm
A staff member at a Rockhampton aged care facility has been diagnosed with pulmonary tuberculosis, sending 29 residents and 42 staff of the facility through screening.
- Tuberculosis Testing Market Research Study including Growth Factors, Types and Application by regions from 2020 to 2025on November 22, 2020 at 10:03 pm
The Tuberculosis Testing market is expected to exceed more than US$ 2900 million by 2024; growing at a CAGR of more than ...
- Can a century-old vaccine for tuberculosis help defeat COVID-19? New research offers some clueson November 22, 2020 at 2:16 pm
While all eyes have been focused on the race to develop a COVID-19 vaccine, other researchers have been furiously working on another way to defeat the coronavirus. It's a vaccine with a very long ...
- Tuberculosis Vaccine Could Mitigate Risk Of Contracting COVID-19, Study Showson November 20, 2020 at 10:27 am
Sinai is showing that a tuberculosis vaccine could help prevent coronavirus infections. The study published Thursday in the Journal of Clinical Investigation found that people who had received the ...
- Study: Tuberculosis vaccine linked to lower risk of contracting COVID-19on November 20, 2020 at 9:51 am
A widely used tuberculosis vaccine is associated with reduced likelihood of contracting COVID-19 (coronavirus), according to a new study by Cedars-Sinai. The findings raise the possibility that a ...
- WHO and other stakeholders join forces to accelerate access to effective paediatric HIV and tuberculosis diagnostics and medicineson November 19, 2020 at 11:57 pm
On World Children’s Day, WHO is pleased to issue a call urging stakeholders to accelerate access to effective paediatric HIV and tuberculosis (TB) diagnostics and medicines.
- Texas A&M Needs Frontline Workers to Test Tuberculosis Vaccine in Fight Against COVID-19on November 19, 2020 at 11:21 am
Texas A&M University researchers are looking for hundreds of first responders and frontline medical workers to join a clinical trial of a current tuberculosis vaccine that could be used in the fight ...
via Google News and Bing News